REPL

Replimune Group, Inc.

12.90 USD

Last updated Sep 12, 05:42 UTC

Yesterday HIGH

$14.47

Yesterday LOW

$13.21

52w HIGH

$16.33

52w LOW

$1.5

EPS

-0.72

PE

-17.92

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Replimune Group, Inc. stock is down -15.08% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

19 Aug 15:57	18 Sep, 2026	15.00	CALL	200	53
19 Aug 18:27	15 Jan, 2027	10.00	CALL	300	17033
19 Aug 19:56	15 Jan, 2027	10.00	CALL	90	17033
19 Aug 19:56	15 Jan, 2027	10.00	CALL	87	17033
19 Aug 19:56	15 Jan, 2027	10.00	CALL	70	17033
19 Aug 19:56	15 Jan, 2027	10.00	CALL	53	17033
27 Aug 19:03	20 Nov, 2026	12.00	CALL	60	331
02 Sep 17:58	21 Jan, 2028	12.00	PUT	84	216
02 Sep 18:31	20 Nov, 2026	15.00	CALL	100	5086
10 Sep 15:34	20 Nov, 2026	14.00	CALL	1000	170

Advanced Data Unlock

Webmaster

Thu Jul 30, 2026

Trading Halt: Halt status updated at 6:45:00 PM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Thu Jul 30, 2026

'US FDA panel backs Replimune skin cancer drug study data'- Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-replimune-skin-cancer-drug-study-data-2026-07-30/
Webmaster

Thu Jul 30, 2026

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
Vandana Singh

Tue Jul 28, 2026

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma ahead of a key advisory committee meeting.
Benzinga Insights

Tue Jul 28, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.
Benzinga Insights

Tue Jul 28, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares moved
Benzinga Insights

Thu Jul 16, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased by 8.51%
Benzinga Insights

Thu Jul 9, 2026

9 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Avi Kapoor

Tue Jun 30, 2026

Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.
Benzinga Newsdesk

Tue Jun 30, 2026

Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9

Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises the price target from $6 to $9.

JP Morgan

Wed Aug 26, 15:38

buy

confirm

Advanced Data Unlock

Philip AstleySparke, Director

Thu Aug 20, 2026

REPL Recent Insider Trades and Stock Chart

50,000 shares gifted
Luisa Emily Hill, Chief Financial Officer

Mon Aug 17, 2026

REPL Recent Insider Trades and Stock Chart

9,256 shares sold
Sushil Patel, Chief Executive Officer

Mon Aug 10, 2026

REPL Recent Insider Trades and Stock Chart

39,341 shares sold
Luisa Emily Hill, Chief Financial Officer

Mon Aug 10, 2026

REPL Recent Insider Trades and Stock Chart

11,448 shares sold
Konstantinos Xynos, Chief Medical Officer

Mon Aug 10, 2026

REPL Recent Insider Trades and Stock Chart

11,447 shares sold
Andrew Schwendenman, Chief Accounting Officer

Mon Aug 10, 2026

REPL Recent Insider Trades and Stock Chart

7,632 shares sold